Innovus Pharma Launches Its Clinically Proven Urivarx Product For Bladder Health Through Its Beyond Human Sales And Marketing Platform In The United States

UriVarx™ Sales Expected to Contribute $3 Million in Annual Revenue

SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of UriVarx™ in the U.S. UriVarx™ is clinically proven to reduce urinary urgency, accidents and both day and night frequency in Overactive Bladder (“OAB”) and Urinary Incontinence (“UI”) patients.

“Bladder health affects millions of people in the U.S. and we believe it is important to offer a natural, yet clinically tested alternative.”

“UriVarx™ is the fifth Innovus product to be launched using our acquired Beyond Human® sales and marketing platform and we believe the product could generate an additional $3.0 million a year in revenues. This launch moves us one step closer to achieving our 2017 goals of $15 million in revenue and profitability,” said Innovus CEO Dr. Bassam Damaj. “Bladder health affects millions of people in the U.S. and we believe it is important to offer a natural, yet clinically tested alternative.”

UriVarx™ has undergone two double blind and comparative trials in both male and female OAB and UI patients. The clinical results include:

1. Reduction of ~56% in Urge Incontinence;
2. Reduction of ~66% in Stress Incontinence;
3. Reduction of ~61% in Urinary Urgency;
4. Reduction of ~33% in Urinary Frequency meaning the total average urinary frequency was in the normal/ideal range after two months of use; and
5. Reduction of ~46% in Nocturia.

According to the Simon Foundation, Urinary Incontinence affects 26 million Americans with a total market size of $1.1 billion (Source: Medical Devices Inc.).

The NAFC (National Association for Continence) estimated that over 33 million Americans suffer from Overactive Bladder with a market size over $2.1 billion (Source: IMS Health).

The product is available through www.urivarx.com and through the Beyond Human® print and online platform reaching between 20-30 million Americans on a monthly basis.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and respiratory diseases. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele® for promoting sexual and cognitive health, (h) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (i) BTH® Vision Formula, (j) BTH® Blood Sugar, (k) UriVarx™ for bladder health, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the UriVarx™ product in the U.S., projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.